Radojica Savic is a medical director with over 17 years of clinical experience, specializing in pediatrics and rare genetic diseases. Currently serving at the PPD clinical research business of Thermo Fisher Scientific, he joined the organization in 2020 and has since played a pivotal role in managing rare disease clinical trials. Dr. Savic’s extensive expertise encompasses protocol development, feasibility studies, patient enrollment, and quality close-out activities.
He obtained his medical degree from the University of Novi Sad, Serbia, where he also completed his internships and residencies in pediatrics and clinical genetics. His professional journey includes significant roles at the Institute for Children and Youth Healthcare of Vojvodina, where he served as a full-time attending physician in the Department of medical genetics and the Pediatric intensive care unit.
Dr. Savic is renowned for his work on rare genetic diseases such as Duchenne muscular dystrophy, Gaucher disease, urea cycle disorders and long-chain fatty acid oxidation disorders, among others. His contributions to clinical genetics and pediatric care have been recognized through numerous publications and presentations. He is committed to advancing medical science and improving patient outcomes through innovative clinical research and strategic medical oversight.
